Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells

  • Xiaojing Yang,

    Affiliations Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research), Biopolis, Singapore, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China

  • R. K. Murthy Karuturi,

    Affiliation Information and Mathematical Science, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research), Biopolis, Singapore

  • Feng Sun,

    Affiliations Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research), Biopolis, Singapore, Department of Pharmacy, National University of Singapore, Singapore, Singapore

  • Meiyee Aau,

    Affiliation Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research), Biopolis, Singapore

  • Kun Yu,

    Affiliation Duke-NUS Graduate Medical School, Singapore, Singapore

  • Rongguang Shao,

    Affiliation Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China

  • Lance D. Miller,

    Affiliation Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research), Biopolis, Singapore

  • Patrick Boon Ooi Tan,

    Affiliations Duke-NUS Graduate Medical School, Singapore, Singapore, Cell and Medical Biology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research), Biopolis, Singapore

  • Qiang Yu

    yuq@gis.a-star.edu.sg

    Affiliation Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research), Biopolis, Singapore

Viewed

Cited

Saved

Discussed

Powered by Altmetric
Questions or concerns about usage data? Please let us know.